Design and in Vitro Biocompatibility of a Novel Ocular Drug Delivery Device
Source abstract
Abstract
The capsule drug ring (CDR) is a reservoir and delivery agent, which is designed to be placed within the capsular bag during cataract surgery. Prototypes were manufactured by hot melt extrusion of Bionate II®, a polycarbonate urethane. The devices have been optimized using Avastin® as the drug of interest. In vitro biocompatibility was assessed with human lens epithelial cell (B-3), mouse macrophage (J774A.1) and mouse fibroblast (L-929) cell lines. Cell migration and proliferation were assessed after in vitro culture. Pro-inflammatory cytokines (i.e., MIP-1β, MIP-1α, MCP-1, IL-1β, TNF and TGF-β1) were quantified using cytometric bead array (CBA). Preliminary in vivo biocompatibility and pharmacokinetics testing has been performed in rabbits.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Corneal Surgery and Treatments · Intraocular Surgery and Lenses · Angiogenesis and VEGF in Cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Bioengineering, University of Utah, Salt Lake City, UT 84112, USA
Moran Eye Center, University of Utah, Salt Lake City, UT 84132, USA
Department of Cardiothoracic Surgery, University of Utah, Salt Lake City, UT 84112, USA
Department of Mechanical Engineering, University of Utah, Salt Lake City, UT 84112, USA
References (18)
Show source-provided references
1. Important causes of visual impairment in the world today
2. The regulation of blood vessel growth by vascular endothelial growth factor10.1111/j.1749-6632.1995.tb17435.x ↗
3. Developments in age-related macular degeneration: Diagnosis and treatment
4. VEGF-A and the induction of pathological angiogenesis10.1146/annurev.pathol.2.010506.134925 ↗
5. Mediators of ocular angiogenesis10.1007/s12041-009-0068-0 ↗
6. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy10.1200/JCO.2002.10.088 ↗
7. VEGF-targeted therapy: Mechanisms of anti-tumour activity10.1038/nrc2403 ↗
8. The biology of VEGF and its receptors10.1038/nm0603-669 ↗
9. Modes of resistance to anti-angiogenic therapy10.1038/nrc2442 ↗
10. Intraocular implants for extended drug delivery: Therapeutic applications10.1016/j.addr.2006.07.026 ↗
11. An experimental platform for systemic drug delivery to the retina10.1073/pnas.0908561106 ↗
12. Formulation and delivery issues for monoclonal antibody therapeutics10.1016/j.addr.2006.03.011 ↗
13. Design and evaluation of polymeric ocular drug delivery system10.1248/cpb.57.914 ↗
14. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device
15. Biodegradable polymers for ocular drug delivery10.1159/000050849 ↗
16. Novel drug delivery systems for glaucoma10.1038/eye.2011.82 ↗
17. An electrochemical intraocular drug delivery device10.1016/j.sna.2007.06.034 ↗
18. Ocular inserts for topical delivery10.1016/0169-409X(95)00014-X ↗